1 active not recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow ARX788: new trials by email Literature Review of ARX788 trials Research Report on ARX788
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients ARX788, Pyrotinib maleate, Trastuzumab - HER2-positive Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Caigang Liu | 136 | 2022-05-23 | 2024-10-30 |
Caigang Liu (1)
China (1)
Caigang Liu, MD (1)